Search and analyze individual stocks with comprehensive metrics
Alkem Laboratories Ltd
Fundamental Score
Alkem Laboratories Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ALKEM across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (19.39%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.38%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (18.30%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Strong Revenue Growth (17.17%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.18)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (22.52x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹6390.70 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.20%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 31.40%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Alkem Laboratories Ltd
About ALKEM
Business Overview
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.
Company Details
Key Leadership
Corporate Events
Latest News
ALKEM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Alkem Laboratories Ltd (ALKEM)?
As of 16 Jan 2026, 10:14 am IST, Alkem Laboratories Ltd (ALKEM) is currently trading at ₹5836.50. The stock has a market capitalization of ₹67.08K (Cr).
Is ALKEM share price Overvalued or Undervalued?
ALKEM is currently trading at a P/E ratio of 28.54x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Alkem Laboratories Ltd share price?
Key factors influencing ALKEM's price include its quarterly earnings growth (Sales Growth: 17.17%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Alkem Laboratories Ltd a good stock for long-term investment?
Alkem Laboratories Ltd shows a 5-year Profit Growth of 13.93% and an ROE of 19.39%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.18 before investing.
How does Alkem Laboratories Ltd compare with its industry peers?
Alkem Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare ALKEM's P/E of 28.54x and ROE of 19.39% against the industry averages to determine its competitive standing.
What is the P/E ratio of ALKEM and what does it mean?
ALKEM has a P/E ratio of 28.54x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹29 for every ₹1 of annual earnings.
How is ALKEM performing according to Bull Run's analysis?
ALKEM has a Bull Run fundamental score of 59.5/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ALKEM belong to?
ALKEM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Alkem Laboratories Ltd.
What is Return on Equity (ROE) and why is it important for ALKEM?
ALKEM has an ROE of 19.39%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Alkem Laboratories Ltd generates profits from shareholders' equity.
How is ALKEM's debt-to-equity ratio and what does it indicate?
ALKEM has a debt-to-equity ratio of 0.18, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is ALKEM's dividend yield and is it a good dividend stock?
ALKEM offers a dividend yield of 0.80%, which means you receive ₹0.80 annual dividend for every ₹100 invested.
How has ALKEM grown over the past 5 years?
ALKEM has achieved 5-year growth rates of: Sales Growth 9.21%, Profit Growth 13.93%, and EPS Growth 13.93%.
What is the promoter holding in ALKEM and why does it matter?
Promoters hold 51.20% of ALKEM shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ALKEM's market capitalization category?
ALKEM has a market capitalization of ₹67075 crores, placing it in the Large-cap category.
How volatile is ALKEM stock?
ALKEM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ALKEM?
ALKEM has a 52-week high of ₹N/A and low of ₹N/A.
What is ALKEM's operating profit margin trend?
ALKEM has a 5-year average Operating Profit Margin (OPM) of 18.30%, indicating the company's operational efficiency.
How is ALKEM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 17.17% and YoY Profit Growth of 11.10%.
What is the institutional holding pattern in ALKEM?
ALKEM has FII holding of 9.47% and DII holding of 21.93%. Significant institutional holding often suggests professional confidence in the stock.